Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Materials
/
Tatva Chintan Pharma Chem
TATVA
Tatva Chintan Pharma Chem
Rising ESG Pressures And Localization Will Erode Export Outlook
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
31 Jul 25
Updated
31 Jul 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
₹535.00
112.6% overvalued
intrinsic discount
31 Jul
₹1,137.60
Loading
1Y
18.8%
7D
-0.6%
Author's Valuation
₹535.0
112.6% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
₹535.0
112.6% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
7b
2018
2020
2022
2024
2025
2026
2028
Revenue ₹6.9b
Earnings ₹515.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
19.55%
Chemicals revenue growth rate
0.46%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
13.44%
Calculation
₹515.29m
Earnings '28
x
34.73x
PE Ratio '28
=
₹17.90b
Market Cap '28
₹17.90b
Market Cap '28
/
23.60m
No. shares '28
=
₹758.33
Share Price '28
₹758.33
Share Price '28
Discounted to 2025 @ 13.30% p.a.
=
₹521.38
Fair Value '25
